Bank of Nova Scotia raised its stake in STERIS plc (NYSE:STE - Free Report) by 382.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,508 shares of the medical equipment provider's stock after purchasing an additional 47,181 shares during the quarter. Bank of Nova Scotia owned about 0.06% of STERIS worth $12,232,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of STERIS in the 4th quarter worth $238,836,000. Raymond James Financial Inc. purchased a new stake in shares of STERIS during the 4th quarter worth about $223,987,000. Franklin Resources Inc. increased its position in STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after purchasing an additional 529,308 shares in the last quarter. Wellington Management Group LLP raised its holdings in STERIS by 4,534.6% in the fourth quarter. Wellington Management Group LLP now owns 219,032 shares of the medical equipment provider's stock valued at $45,024,000 after buying an additional 214,306 shares during the period. Finally, Boston Trust Walden Corp lifted its position in STERIS by 400.4% during the fourth quarter. Boston Trust Walden Corp now owns 224,741 shares of the medical equipment provider's stock valued at $46,198,000 after buying an additional 179,829 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on STE shares. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Stephens reissued an "overweight" rating and set a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price target on shares of STERIS in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, STERIS has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.
Read Our Latest Research Report on STE
STERIS Stock Down 1.3 %
Shares of NYSE:STE traded down $2.85 during midday trading on Tuesday, reaching $221.17. The company had a trading volume of 197,925 shares, compared to its average volume of 533,910. The stock has a market capitalization of $21.73 billion, a P/E ratio of 46.96 and a beta of 0.87. The stock's fifty day moving average price is $222.67 and its 200-day moving average price is $219.40. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. STERIS plc has a one year low of $197.82 and a one year high of $248.24.
STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Equities research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.03%. The ex-dividend date was Thursday, February 20th. STERIS's dividend payout ratio is currently 48.41%.
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
